Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy
Top Cited Papers
- 29 July 2005
- journal article
- review article
- Published by Elsevier BV in Biochemical and Biophysical Research Communications
- Vol. 333 (2), 328-335
- https://doi.org/10.1016/j.bbrc.2005.05.132
Abstract
No abstract availableKeywords
This publication has 69 references indexed in Scilit:
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Reviews Drug Discovery, 2004
- A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal CancerJournal of Clinical Oncology, 2004
- OncogenicrasFails to Restore anin VivoTumorigenic Phenotype in Embryonic Stem Cells Lacking Vascular Endothelial Growth Factor (VEGF)Biochemical and Biophysical Research Communications, 1999
- The Carboxyl-terminal Domain(111–165) of Vascular Endothelial Growth Factor Is Critical for Its Mitogenic PotencyOnline Journal of Public Health Informatics, 1996
- Both v-Ha-Ras and v-Raf Stimulate Expression of the Vascular Endothelial Growth Factor in NIH 3T3 CellsOnline Journal of Public Health Informatics, 1995
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993
- Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factorBiochemical and Biophysical Research Communications, 1992
- The fms -Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth FactorScience, 1992
- Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cellsBiochemical and Biophysical Research Communications, 1989
- Tumor Angiogenesis: Therapeutic ImplicationsThe New England Journal of Medicine, 1971